PT1477187E - Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos - Google Patents

Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos Download PDF

Info

Publication number
PT1477187E
PT1477187E PT04019466T PT04019466T PT1477187E PT 1477187 E PT1477187 E PT 1477187E PT 04019466 T PT04019466 T PT 04019466T PT 04019466 T PT04019466 T PT 04019466T PT 1477187 E PT1477187 E PT 1477187E
Authority
PT
Portugal
Prior art keywords
implant
drugs
formulation
controlled release
hydrophobic agents
Prior art date
Application number
PT04019466T
Other languages
English (en)
Inventor
Vernon G Wong
Frank Kochinke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23823541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1477187(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of PT1477187E publication Critical patent/PT1477187E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
PT04019466T 1995-06-02 1996-05-31 Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos PT1477187E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/459,134 US5869079A (en) 1995-06-02 1995-06-02 Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents

Publications (1)

Publication Number Publication Date
PT1477187E true PT1477187E (pt) 2011-09-01

Family

ID=23823541

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04019466T PT1477187E (pt) 1995-06-02 1996-05-31 Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos

Country Status (18)

Country Link
US (9) US5869079A (pt)
EP (4) EP2298353A1 (pt)
JP (3) JPH11506450A (pt)
KR (1) KR19990022212A (pt)
CN (1) CN1191492A (pt)
AT (2) ATE516049T1 (pt)
AU (1) AU721421B2 (pt)
BR (1) BR9608642A (pt)
CA (2) CA2222889C (pt)
DE (1) DE69635734T3 (pt)
DK (1) DK1477187T3 (pt)
ES (2) ES2256859T5 (pt)
MY (1) MY132179A (pt)
PL (1) PL323747A1 (pt)
PT (1) PT1477187E (pt)
RU (1) RU2175561C2 (pt)
TW (1) TW487580B (pt)
WO (1) WO1996038174A1 (pt)

Families Citing this family (340)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
AU722303C (en) * 1996-03-05 2001-12-06 Robert Gurny Pharmaceutical compositions containing buffered ortho ester polymers
FR2748205A1 (fr) * 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5942508A (en) * 1997-02-04 1999-08-24 Senju Pharmaceutical Co., Ltd. Method for solubilizing pyridonecarboxylic acid solubilizer thereof and aqueous solution containing solubilized pyridonecarboxylic acid
CA2300154C (en) * 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US7445792B2 (en) * 2003-03-10 2008-11-04 Abbott Laboratories Medical device having a hydration inhibitor
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7399480B2 (en) * 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
ATE315386T1 (de) 1998-08-06 2006-02-15 Joerg Dr Dr Schierholz Medizinprodukte mit retardierter pharmakologischer aktivität und verfahren zu ihrer herstellung
EP0985413A1 (de) * 1998-08-06 2000-03-15 Jörg Michael Dr. Dr. Schierholz Medizinprodukte mit retardierter pharmakologischer Aktivität und Verfahren zu ihrer Herstellung
US7455853B2 (en) * 1998-09-24 2008-11-25 Abbott Cardiovascular Systems Inc. Medical devices containing rapamycin analogs
FR2770134B1 (fr) * 1998-10-28 2002-06-07 Delab Formulations solides ou semi-solides pour administration locale
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
US6113638A (en) * 1999-02-26 2000-09-05 Williams; Lytton A. Method and apparatus for intervertebral implant anchorage
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US20010049422A1 (en) * 2000-04-14 2001-12-06 Phaneuf Matthew D. Methods of applying antibiotic compounds to polyurethane biomaterials using textile dyeing technology
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040033241A1 (en) * 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
EP3167872B1 (en) 2000-07-05 2020-10-14 Allergan, Inc. Methods for treating inflammation-mediated conditions of the eye
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
EP1621219A3 (en) * 2000-11-29 2006-03-22 Allergan, Inc. Intraocular implants for preventing transplant rejection in the eye
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US20020082678A1 (en) * 2000-12-22 2002-06-27 Motasim Sirhan Intravascular delivery of mizoribine
JP4657577B2 (ja) * 2001-01-09 2011-03-23 マイクロチップス・インコーポレーテッド 眼への適用および他への適用のための可撓性マイクロチップデバイス
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP1387671A1 (en) 2001-05-03 2004-02-11 MASSACHUSETTS EYE & EAR INFIRMARY Implantable drug delivery device and use thereof
US7592016B2 (en) * 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
GB0116920D0 (en) * 2001-07-11 2001-09-05 Sulzer Vascutek Ltd Delivery system
US20080145402A1 (en) * 2001-09-10 2008-06-19 Abbott Cardiovascular Systems Inc. Medical Devices Containing Rapamycin Analogs
ES2393086T3 (es) * 2002-02-22 2012-12-18 Santen Pharmaceutical Co., Ltd. Sistema de administración de fármaco destinado a la administración subconjuntival de granos finos
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
EP2522319A3 (en) * 2002-03-11 2013-09-25 Novartis AG Implantable drug delivery system
US7074426B2 (en) * 2002-03-27 2006-07-11 Frank Kochinke Methods and drug delivery systems for the treatment of orofacial diseases
AU2003217531A1 (en) * 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
EP1507826A4 (en) 2002-05-17 2007-11-07 Othera Pharmaceuticals Inc IMPROVING THE EVOLUTION OF CATARACTS AND OTHER OPHTHALMIC DISEASES
BR0311722A (pt) * 2002-06-13 2005-03-01 Novartis Ag Compostos de ciclodextrina com amÈnia quaternizado
BR0312635A (pt) * 2002-07-15 2005-04-19 Alcon Inc Composições de implante farmacêutico lipofìlico não polimérico para uso intraocular
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
DE10238310A1 (de) * 2002-08-21 2004-03-04 Erich Jaeger Gmbh Elektrodenanordnung
CZ294328B6 (cs) * 2002-08-22 2004-11-10 Pliva-Lachema A. S. Biodegradabilní kompozice s prolongovaným uvolňováním biologicky aktivní látky a způsob její výroby
PL375698A1 (en) * 2002-09-06 2005-12-12 Abbott Laboratories Medical device having hydration inhibitor
CA2689424A1 (en) * 2002-09-29 2004-04-08 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
WO2004036182A2 (en) * 2002-10-17 2004-04-29 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
CA2501298A1 (en) * 2002-10-17 2004-04-29 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
CA2508303C (en) * 2002-12-04 2012-10-23 Santen Pharmaceutical Co., Ltd. Drug delivery system using subconjunctival depot
JP2004196787A (ja) * 2002-12-04 2004-07-15 Santen Pharmaceut Co Ltd 結膜下デポによるドラッグデリバリーシステム
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
EP1594484A2 (en) * 2003-02-17 2005-11-16 Cipla Ltd. Pharmaceutical patch
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US8012115B2 (en) * 2003-02-18 2011-09-06 S.K. Pharmaceuticals, Inc. Optic nerve implants
CA2516790A1 (en) * 2003-02-20 2004-09-02 Alcon, Inc. Formulations of glucocorticoids to treat pathologic ocular angiogenesis
BRPI0407693A (pt) * 2003-02-20 2006-03-01 Alcon Inc uso de esteróides para preparação de formulações utilizáveis no tratamento de pessoas sofrendo de distúrbios oculares, bem como formulação assim obtidos
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US7825134B2 (en) * 2003-05-19 2010-11-02 Othera Holding, Inc. Amelioration of cataracts, macular degeneration and other ophthalmic diseases
EP1633339A4 (en) * 2003-06-13 2009-06-03 Alcon Inc FORMULATIONS OF NON-TEROIDAL ANTI-RHEUMATICS FOR THE TREATMENT OF PATHOLOGICAL OCCULAR ANGIOGENESIS
US20040253293A1 (en) * 2003-06-16 2004-12-16 Afshin Shafiee Rate controlled release of a pharmaceutical agent in a biodegradable device
US7875272B2 (en) * 2003-06-27 2011-01-25 Ethicon, Incorporated Treatment of stroke and other acute neuraldegenerative disorders using postpartum derived cells
US9592258B2 (en) 2003-06-27 2017-03-14 DePuy Synthes Products, Inc. Treatment of neurological injury by administration of human umbilical cord tissue-derived cells
US8491883B2 (en) * 2003-06-27 2013-07-23 Advanced Technologies And Regenerative Medicine, Llc Treatment of amyotrophic lateral sclerosis using umbilical derived cells
PL1641914T3 (pl) 2003-06-27 2017-01-31 DePuy Synthes Products, Inc. Komórki pochodzące z poporodowej tkanki łożyska oraz sposoby uzyskiwania i zastosowania tych komórek
US8790637B2 (en) * 2003-06-27 2014-07-29 DePuy Synthes Products, LLC Repair and regeneration of ocular tissue using postpartum-derived cells
US8518390B2 (en) 2003-06-27 2013-08-27 Advanced Technologies And Regenerative Medicine, Llc Treatment of stroke and other acute neural degenerative disorders via intranasal administration of umbilical cord-derived cells
US9572840B2 (en) 2003-06-27 2017-02-21 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue using postpartum-derived cells
CA2536185C (en) * 2003-08-20 2012-06-26 Santen Pharmaceutical Co., Ltd. Drug delivery system by administrating fine particles to sub-tenon
US20050209141A1 (en) * 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20090148527A1 (en) * 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050130906A1 (en) * 2003-11-20 2005-06-16 Matier William L. Amelioration of macular degeneration and other ophthalmic diseases
CA2552435A1 (en) 2003-12-05 2005-06-23 Compound Therapeutics, Inc. Inhibitors of type 2 vascular endothelial growth factor receptors
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
US8691258B2 (en) * 2003-12-12 2014-04-08 Medtronic, Inc. Anti-infective medical device
WO2005061003A1 (en) * 2003-12-12 2005-07-07 Medtronic, Inc. Anti-infective medical device
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
AU2011213904B2 (en) * 2004-04-30 2014-06-05 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US7771742B2 (en) * 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8147865B2 (en) * 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20070254950A1 (en) * 2004-05-25 2007-11-01 Othera Pharmaceuticals, Inc. Oculoselective Drugs and Prodrugs
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
AU2013221985B2 (en) * 2004-07-12 2016-09-01 Allergan, Inc. Ophthalmic compositions and methods for treating ophthalmic conditions
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
US20060116404A1 (en) 2004-09-24 2006-06-01 Gary Robinson CAI-based systems and methods for the localized treatment of ocular and other diseases
US20060068012A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly (vinyl alcohol) drug delivery devices with humidity control
US20060067978A1 (en) * 2004-09-29 2006-03-30 Bausch & Lomb Incorporated Process for preparing poly(vinyl alcohol) drug delivery devices
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
MX2007003968A (es) 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
CA2590136A1 (en) * 2004-12-10 2006-06-15 Talima Therapeutics, Inc. Compositions and methods for treating conditions of the nail unit
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
WO2006083394A2 (en) * 2004-12-21 2006-08-10 Ethicon, Inc. Postpartum cells derived from placental tissue, and methods of making, culturing, and using the same
US20060153815A1 (en) * 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
US20060171930A1 (en) * 2004-12-21 2006-08-03 Agnieszka Seyda Postpartum cells derived from umbilical cord tissue, and methods of making, culturing, and using the same
US20060134175A1 (en) * 2004-12-22 2006-06-22 Stephen Bartels Drug eluting pharmaceutical delivery system for treatment of ocular disease and method of use
US20060134174A1 (en) * 2004-12-22 2006-06-22 Bausch & Lomb Incorporated Pharmaceutical delivery system and method of use
PL1835924T3 (pl) 2004-12-23 2014-01-31 Ethicon Incorporated Leczenie choroby Parkinsona i zaburzeń związanych z tą chorobą z użyciem komórek uzyskiwanych po porodzie
ES2621847T3 (es) 2004-12-23 2017-07-05 DePuy Synthes Products, Inc. Células posparto derivadas de tejido de cordón umbilical, y métodos de elaboración y uso de las mismas
US20060165810A1 (en) * 2004-12-28 2006-07-27 The Trustees Of The University Of Pennsylvania Controlled release from block co-polymer worm micelles
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
JP2008535847A (ja) * 2005-04-08 2008-09-04 サーモディクス，インコーポレイティド 網膜下に送達するための持続放出インプラント
US7931909B2 (en) * 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
WO2007014327A2 (en) 2005-07-27 2007-02-01 University Of Florida Research Foundation, Inc. Small compounds that correct protein misfolding and uses thereof
AU2006295305B2 (en) * 2005-09-16 2013-01-31 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
EP1937244B1 (en) 2005-09-30 2018-07-25 Io Therapeutics, LLC Treatment of cancer with specific rxr agonists
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2007047626A1 (en) * 2005-10-14 2007-04-26 Alcon, Inc. Combination treatment with anecortave acetate and bevacizumab or ranibizumab for pathologic ocular angiogenesis
CN101394834A (zh) 2005-10-18 2009-03-25 阿勒根公司 用糖皮质激素衍生物选择性渗透后段组织来治疗眼睛
CA2631173A1 (en) 2005-11-29 2007-06-07 Smithkline Beecham Corporation Treatment method
EP1971681B1 (en) * 2005-12-16 2017-08-23 DePuy Synthes Products, Inc. Compositions and methods for inhibiting adverse immune response in histocompatibility-mismatched transplantation
US8741638B2 (en) * 2005-12-19 2014-06-03 DePuy Synthes Products, LLC In vitro expansion of postpartum-derived cells in roller bottles
AU2006330409B2 (en) * 2005-12-28 2012-07-19 Ethicon, Incorporated Treatment of peripheral vascular disease using postpartum-derived cells
US9125906B2 (en) 2005-12-28 2015-09-08 DePuy Synthes Products, Inc. Treatment of peripheral vascular disease using umbilical cord tissue-derived cells
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
JP2009531283A (ja) 2006-02-02 2009-09-03 アラーガン、インコーポレイテッド 眼系疾患の処置のための組成物および方法
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
WO2008060359A2 (en) * 2006-09-29 2008-05-22 Surmodics, Inc. Biodegradable ocular implants and methods for treating ocular conditions
ATE539102T1 (de) 2006-10-31 2012-01-15 Surmodics Pharmaceuticals Inc Kugelförmige polymer-partikel
US8586556B2 (en) 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2121743B1 (en) 2006-11-22 2015-06-03 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including igf-ir
WO2008070479A2 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
EP2125716A2 (en) 2007-02-22 2009-12-02 Othera Holding, Inc. Hydroxylamine compounds and methods of their use
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
WO2008143906A2 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed particles for controlled release of ophthalmic medications
US8231892B2 (en) * 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
US8329220B2 (en) * 2007-08-24 2012-12-11 Aegis Therapeutics, Llc Controlled release formulations
US20090123508A1 (en) * 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
BRPI0818183A2 (pt) * 2007-10-05 2019-07-16 Ethicon Inc reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
US8236538B2 (en) * 2007-12-20 2012-08-07 Advanced Technologies And Regenerative Medicine, Llc Methods for sterilizing materials containing biologically active agents
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
US9192571B2 (en) 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
WO2009140246A2 (en) 2008-05-12 2009-11-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
US8821870B2 (en) 2008-07-18 2014-09-02 Allergan, Inc. Method for treating atrophic age related macular degeneration
EP2320911B1 (en) 2008-08-01 2014-10-08 Eye Therapies LLC Vasoconstriction compositions and methods of use
CA2738766A1 (en) * 2008-09-25 2010-04-01 Invivo Therapeutics Corporation Spinal cord injury, inflammation, and immune-disease: local controlled release of therapeutic agents
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
CA2747794C (en) 2008-12-19 2018-10-30 Advanced Technologies And Regenerative Medicine, Llc Treatment of lung and pulmonary diseases and disorders
US10179900B2 (en) * 2008-12-19 2019-01-15 DePuy Synthes Products, Inc. Conditioned media and methods of making a conditioned media
EP2379089B1 (en) * 2008-12-19 2019-04-17 DePuy Synthes Products, Inc. Regeneration and repair of neural tissue following injury
BRPI0923177A2 (pt) * 2008-12-19 2020-08-25 Advanced Technologies And Regenerative Medicine, Llc usos de composições para tratar dor neuropática e espacidade, as referidas composições, e kit
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100239632A1 (en) * 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
CA2756600C (en) 2009-03-26 2019-08-20 Advanced Technologies And Regenerative Medicine, Llc Human umbilical cord tissue cells as therapy for alzheimer's disease
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US9017725B2 (en) * 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
IN2012DN00352A (pt) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
GB201111485D0 (en) 2011-07-05 2011-08-17 Biocopea Ltd Drug composition and its use in therapy
CA2803059A1 (en) 2009-06-19 2010-12-23 Altos Vision Limited Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
EP2461800A2 (en) * 2009-08-05 2012-06-13 Pieris AG Controlled release formulations of lipocalin muteins
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
WO2011048070A1 (en) 2009-10-20 2011-04-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of disorders of glucose homeostasis
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
EP2512389B1 (en) 2009-12-16 2015-09-02 Allergan, Inc. Intracameral devices for sustained delivery
KR20180117211A (ko) 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US9328162B2 (en) 2010-02-25 2016-05-03 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
KR101876693B1 (ko) 2010-03-08 2018-07-09 스펙트럼 파마슈티컬즈 인크 암을 치료하기 위한 티옥산톤계 자가포식작용 저해제 치료제
CA2798145C (en) 2010-05-04 2022-10-18 Corium International, Inc. Method and device for transdermal delivery of parathyroid hormone using a microprojection array
WO2011141456A1 (en) 2010-05-10 2011-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6023703B2 (ja) 2010-05-26 2016-11-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改善された安定性を有するフィブロネクチンをベースとする足場タンパク質
WO2011159824A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. Composition and method for treating overactive bladder
WO2011163560A1 (en) 2010-06-25 2011-12-29 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Methods of treatment using sterculic acid
US8946170B2 (en) 2010-07-21 2015-02-03 Allergan, Inc. Sustained release siRNA for ocular drug delivery
US8697056B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8697057B2 (en) 2010-08-19 2014-04-15 Allergan, Inc. Compositions and soft tissue replacement methods
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US20140024627A1 (en) 2011-01-03 2014-01-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
US9194058B2 (en) 2011-01-31 2015-11-24 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
US9034240B2 (en) 2011-01-31 2015-05-19 Arsenal Medical, Inc. Electrospinning process for fiber manufacture
US8968626B2 (en) 2011-01-31 2015-03-03 Arsenal Medical, Inc. Electrospinning process for manufacture of multi-layered structures
WO2012112757A2 (en) 2011-02-17 2012-08-23 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2678022A2 (en) 2011-02-23 2014-01-01 Allergan, Inc. Compositions and improved soft tissue replacement methods
TW201311295A (zh) 2011-06-03 2013-03-16 Allergan Inc 對皮脂腺之類視色素化合物之目標遞送
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
BR112013032199A2 (pt) 2011-06-14 2017-12-12 Bikam Pharmaceuticals Inc ligantes de ligação à opsina, composições e métodos de utilização
WO2012177825A1 (en) 2011-06-21 2012-12-27 Bvw Holding Ag Medical device comprising boswellic acid
EP2734261B1 (en) 2011-07-18 2018-02-21 Mor-Research Applications Ltd. A device for adjusting the intraocular pressure
AU2012325341B2 (en) 2011-10-19 2017-01-05 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US8993831B2 (en) 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
JP6322142B2 (ja) 2011-12-01 2018-05-09 ビカム ファーマスーティカルス，インコーポレイテッド オプシン結合性リガンド、組成物、及び使用方法
EP3613413A1 (en) 2011-12-05 2020-02-26 Incept, LLC Medical organogel processes and compositions
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
ES2676556T3 (es) 2011-12-23 2018-07-20 Depuy Synthes Products Llc Detección de células derivadas de tejido del cordón umbilical humano
CN104204099A (zh) * 2012-01-13 2014-12-10 密苏里大学管委会 抗生物膜形成的低温等离子体涂层
EP2814482A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
EP2814510A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123275A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
WO2013123274A1 (en) 2012-02-16 2013-08-22 Allergan, Inc. Compositions and improved soft tissue replacement methods
NZ706067A (en) 2012-09-26 2016-07-29 Tangent Reprofiling Ltd Modulators of androgen synthesis
TWI663985B (zh) * 2012-09-27 2019-07-01 美商歐樂根公司 用於持續釋放蛋白質之可生物降解的藥物傳遞系統
CA2887893C (en) 2012-10-09 2021-07-06 Douglas SEARS Therapeutic treatment for attention deficit disorder
AU2013336683A1 (en) 2012-10-24 2015-05-14 Biocopea Limited Drug combinations containing statins for treating cardiovascular diseases
EP3660033B9 (en) 2012-11-15 2022-06-22 Apellis Pharmaceuticals, Inc. Long-acting compstatin analogs and related compositions and methods
AU2013364053B2 (en) 2012-12-21 2018-08-30 Corium Pharma Solutions, Inc. Microarray for delivery of therapeutic agent and methods of use
JP6513576B2 (ja) 2013-01-14 2019-05-15 ヘルス クリニックス リミテッド 抗がん剤および使用
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
NZ710658A (en) 2013-02-18 2019-12-20 Vegenics Pty Ltd Ligand binding molecules and uses thereof
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
EP2970145B1 (en) 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
CN105142711B (zh) 2013-03-12 2019-01-22 考里安国际公司 微突起施加器
US9655999B2 (en) 2013-03-12 2017-05-23 Carnegie Mellon University Coated vaso-occlusive device for treatment of aneurysms
CA2904703A1 (en) 2013-03-14 2014-10-02 Hallux, Inc. Method of treating infections, diseases or disorders of nail unit
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CA2906541C (en) 2013-03-15 2022-06-21 Corium International, Inc. Microarray for delivery of therapeutic agent and methods of use
WO2014151769A1 (en) 2013-03-15 2014-09-25 Allergan, Inc. Compositions including encapsulated isotretinoin and methods for use thereof
WO2014182635A1 (en) 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
CN105530867B (zh) 2013-08-21 2018-11-13 传感技术股份有限公司 用于生物感测分析物的体内保护的药物洗脱
JP6543431B2 (ja) * 2013-10-10 2019-07-10 ユニバーシティー オブ ユタ リサーチ ファウンデーションＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｕｔａｈ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 眼内薬物送達デバイスおよび付随する方法
EP3099290A1 (en) 2014-01-28 2016-12-07 Allergan, Inc. Topical retinoid formulations and methods of use
CA2939219C (en) 2014-02-11 2023-02-28 Mitokinin Llc Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
US10668157B2 (en) 2014-04-17 2020-06-02 Seed Co., Ltd. Anionic drug-containing medical device
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20160008376A1 (en) 2014-07-10 2016-01-14 Biocopea Limited Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders
US10624843B2 (en) 2014-09-04 2020-04-21 Corium, Inc. Microstructure array, methods of making, and methods of use
BR112017019025A2 (pt) 2015-03-06 2018-07-31 Envisia Therapeutics Inc aplicadores de implante e métodos para administrar implantes.
US10857093B2 (en) 2015-06-29 2020-12-08 Corium, Inc. Microarray for delivery of therapeutic agent, methods of use, and methods of making
CA2993340C (en) 2015-07-23 2024-04-30 Aerie Pharmaceuticals, Inc. Intravitreal drug delivery systems for the treatment of ocular conditions
RU2749674C2 (ru) 2015-07-29 2021-06-16 Аллерган, Инк. Антитела против ang-2, содержащие только тяжелую цепь
EP3334762A1 (en) 2015-08-14 2018-06-20 Allergan, Inc. Heavy chain only antibodies to pdgf
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
CN114773318A (zh) 2015-09-02 2022-07-22 特维娜有限公司 含有六元氮杂杂环的δ阿片受体调节化合物、其使用和制备方法
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
EP3359555B1 (en) 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
US12048761B2 (en) * 2015-10-13 2024-07-30 Inserm (Institut National De La Santé Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
EP4088719A1 (en) 2015-10-13 2022-11-16 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
NZ741393A (en) 2015-10-31 2018-11-30 Io Therapeutics Inc Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones
PT109154B (pt) * 2016-02-12 2019-11-05 Univ De Coimbra Tecnologia não-invasiva de inserto ocular para libertação controlada de fármacos
WO2017155578A1 (en) 2016-03-10 2017-09-14 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
EP3426302B1 (en) 2016-03-10 2022-12-14 IO Therapeutics, Inc. Treatment of autoimmune diseases with combinations of rxr agonists and thyroid hormones
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
US20190125669A1 (en) * 2016-04-17 2019-05-02 Children's Medical Center Corporation Systems and methods for steroidal gels
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
EP3481405A1 (en) 2016-07-05 2019-05-15 Janssen Biotech, Inc. Treatment of retinal vascular disease using progenitor cells
JP7100019B2 (ja) 2016-08-19 2022-07-12 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
AU2018221148B2 (en) 2017-02-17 2022-05-05 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
BR112019016775A2 (pt) 2017-02-17 2020-03-31 Trevena, Inc. Compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 7 membros, métodos de uso e produção dos mesmos
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
AU2018261022B2 (en) 2017-05-05 2024-02-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Ocular applications of matrix bound vesicles (MBVs)
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
EP3641545A4 (en) 2017-06-21 2021-02-24 Mitokinin, Inc. COMPOSITIONS AND METHODS USING THEM FOR THE TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE
CA3072673A1 (en) 2017-08-11 2019-02-14 Unity Biotechnology, Inc. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
US20220104839A1 (en) 2017-10-16 2022-04-07 Retriever Medical, Inc. Clot Removal Methods and Devices with Multiple Independently Controllable Elements
US10172634B1 (en) 2017-10-16 2019-01-08 Michael Bruce Horowitz Catheter based retrieval device with proximal body having axial freedom of movement
AU2021362245A1 (en) 2017-10-16 2023-05-25 Retriever Medical, Inc. Clot removal methods and devices with multiple independently controllable elements
CA3082643A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
JP7356994B2 (ja) 2018-03-02 2023-10-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 網膜炎症および神経変性を処置するためのｉｌ－３４の使用
CN112423740A (zh) * 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法
EP3873342A4 (en) 2018-11-02 2022-08-10 Senseonics, Incorporated DRUG ELUTING MATRIX ON AN ANALYTICAL INDICATOR
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof
BR112022011067A2 (pt) * 2019-12-10 2022-08-23 Alcon Inc Insertos oculares poliméricos dissolvíveis com um polímero biodegradável
CA3165922A1 (en) 2020-01-17 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of crx-autosomal dominant retinopathies
EP4157309A1 (en) 2020-06-01 2023-04-05 Black Cat Bio Limited Compositions and methods for treating infections and netopathy
WO2023105417A1 (en) 2021-12-06 2023-06-15 Breye Therapeutics Aps Danegaptide formulation for applicatoin in the eye
KR20240119103A (ko) 2021-12-07 2024-08-06 아이오 테라퓨틱스, 인크. Her2+ 암 치료에서의 rxr 작용제 및 탁산의 용도
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
US11779553B1 (en) * 2022-11-28 2023-10-10 Atif B. D. Collins Methods and devices for treatment of eyelid ptosis
WO2024196814A1 (en) 2023-03-17 2024-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treatment of age-related macular degeneration

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL297357A (pt) * 1962-08-31
US3416530A (en) * 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3960150A (en) * 1971-09-09 1976-06-01 Alza Corporation Bioerodible ocular device
US3986510A (en) * 1971-09-09 1976-10-19 Alza Corporation Bioerodible ocular device
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3914402A (en) * 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
SE390255B (sv) * 1974-02-18 1976-12-13 N G Y Torphammar Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon
US3961628A (en) * 1974-04-10 1976-06-08 Alza Corporation Ocular drug dispensing system
US3921632A (en) * 1974-08-16 1975-11-25 Frank M Bardani Implant device
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4180646A (en) * 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4201210A (en) * 1976-06-22 1980-05-06 The United States Of America As Represented By The Secretary Of Agriculture Veterinary ocular ring device for sustained drug release
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4402979A (en) * 1980-03-21 1983-09-06 Merck & Co., Inc. & Laboratories Ophthalmic formulations of 5-fluoro-2-methyl-1-(p-methylthiobenzylidene)-3-indenylacetic acid
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) * 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ｔｔｌオ−トストロボ用絞り制御回路
US4451254A (en) * 1982-03-15 1984-05-29 Eli Lilly And Company Implant system
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
US4530840A (en) * 1982-07-29 1985-07-23 The Stolle Research And Development Corporation Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5082655A (en) * 1984-07-23 1992-01-21 Zetachron, Inc. Pharmaceutical composition for drugs subject to supercooling
US4668506A (en) * 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
US4966849A (en) * 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US4640941A (en) * 1985-11-25 1987-02-03 Alcon Laboratories Hydrogels containing siloxane comonomers
DE3612212A1 (de) * 1986-04-11 1987-10-15 Basf Ag Verfahren zur herstellung von festen pharmazeutischen formen
US4756911A (en) * 1986-04-16 1988-07-12 E. R. Squibb & Sons, Inc. Controlled release formulation
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US5322691A (en) * 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US4863457A (en) * 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
US4821210A (en) * 1987-04-02 1989-04-11 General Electric Co. Fast display of three-dimensional images
DE3851152T2 (de) * 1987-09-03 1995-01-26 Univ Georgia Cyclosporin-augenmittel.
DE3734223A1 (de) * 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4945089A (en) * 1987-12-29 1990-07-31 Alcon Laboratories, Inc. Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
GB8820353D0 (en) * 1988-08-26 1988-09-28 Staniforth J N Controlled release tablet
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
SG49267A1 (en) * 1989-08-14 1998-05-18 Photogenesis Inc Surgical instrument and cell isolation and transplantation
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5268178A (en) * 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5660851A (en) * 1989-12-26 1997-08-26 Yissum Research Development Company Of The Hebrew Univ. Of Jerusalem Ocular inserts
US5075115A (en) * 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
ES2062634T3 (es) † 1990-08-30 1994-12-16 Senju Pharma Co Composicion con liberacion controlada del farmaco.
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
JP3351525B2 (ja) * 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
US5356629A (en) * 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) * 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US6045791A (en) * 1992-03-06 2000-04-04 Photogenesis, Inc. Retinal pigment epithelium transplantation
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE69331387T2 (de) * 1992-09-10 2002-08-22 Childrens Medical Center Biodegradierbare polymeren matrizen mit verzoegerter freisetzung von lokalanaesthetika
US5688819A (en) * 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5314419A (en) * 1992-10-30 1994-05-24 Pelling George E Method for dispensing ophthalmic drugs to the eye
US5601844A (en) * 1992-11-18 1997-02-11 Fujisawa Pharmaceutical Co., Ltd. Sustained release medicinal preparation
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5456917A (en) * 1993-04-12 1995-10-10 Cambridge Scientific, Inc. Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
US5385887A (en) * 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5393765A (en) † 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (de) * 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraokulare Linsenanordnung zur Astigmatismuskorrektur
US5773021A (en) * 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5466233A (en) * 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5755785A (en) * 1994-08-12 1998-05-26 The University Of South Florida Sutureless corneal transplantation method
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
CA2149164C (en) * 1995-05-11 2009-03-03 Zlatko Korunic Diatomaceous earth insecticidal composition
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
US5693335A (en) * 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5941250A (en) * 1996-11-21 1999-08-24 University Of Louisville Research Foundation Inc. Retinal tissue implantation method
EP0973499B1 (en) * 1997-03-31 2003-08-06 Alza Corporation Diffusional implantable delivery system
CA2300154C (en) * 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
JP3937533B2 (ja) * 1997-11-07 2007-06-27 セイコーエプソン株式会社 遠隔座標入力装置および遠隔座標入力方法
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
EP1131114B1 (en) * 1998-11-20 2004-06-16 The University of Connecticut Apparatus and method for control of tissue/implant interactions
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US7335803B2 (en) * 2001-10-19 2008-02-26 Allergan, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US6545182B2 (en) * 2000-04-13 2003-04-08 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6534542B2 (en) * 2001-02-27 2003-03-18 Allergen Sales, Inc. (2-hydroxy)ethyl-thioureas useful as modulators of α2B adrenergic receptors
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
US7386835B1 (en) * 2002-03-22 2008-06-10 Emc Corporation Technique for graphical user interface modification
US6541504B1 (en) * 2002-04-03 2003-04-01 Allergan Sales, Llc (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7276522B2 (en) * 2002-05-21 2007-10-02 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones, 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US20040048099A1 (en) * 2002-08-29 2004-03-11 Chen Jian Ping Organic light-emitting device using iptycene derivatives
AU2003295409B2 (en) * 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050058696A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007518804A (ja) * 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7993634B2 (en) * 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
JP2008505978A (ja) * 2004-07-12 2008-02-28 アラーガン、インコーポレイテッド 眼病用組成物および眼病治療法
US7357394B2 (en) * 2004-10-01 2008-04-15 Sri Acquisition Corp. Modular shooting range
US20060233857A1 (en) * 2005-04-14 2006-10-19 Amsden Brian G Degradable elastomeric network
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods

Also Published As

Publication number Publication date
ES2368951T3 (es) 2011-11-23
ES2256859T3 (es) 2006-07-16
EP1477187A1 (en) 2004-11-17
DE69635734T2 (de) 2006-07-13
EP1637164A2 (en) 2006-03-22
BR9608642A (pt) 1999-08-24
TW487580B (en) 2002-05-21
JPH11506450A (ja) 1999-06-08
KR19990022212A (ko) 1999-03-25
DE69635734T3 (de) 2009-04-23
EP0831912A4 (en) 2000-08-30
DE69635734D1 (de) 2006-04-06
US20050191334A1 (en) 2005-09-01
EP0831912B1 (en) 2006-01-11
US7048946B1 (en) 2006-05-23
CA2222889C (en) 2012-01-03
JP2006192282A (ja) 2006-07-27
ATE516049T1 (de) 2011-07-15
US20030095995A1 (en) 2003-05-22
AU721421B2 (en) 2000-07-06
EP1637164A3 (en) 2007-09-05
ES2256859T5 (es) 2009-04-01
WO1996038174A1 (en) 1996-12-05
US5869079A (en) 1999-02-09
AU5962496A (en) 1996-12-18
JP2011005300A (ja) 2011-01-13
MY132179A (en) 2007-09-28
CN1191492A (zh) 1998-08-26
EP1477187B1 (en) 2011-07-13
EP0831912B2 (en) 2008-10-29
ATE315409T1 (de) 2006-02-15
MX9709218A (es) 1998-06-30
EP0831912A1 (en) 1998-04-01
US20050048098A1 (en) 2005-03-03
PL323747A1 (en) 1998-04-14
US20080124377A1 (en) 2008-05-29
EP1477187B9 (en) 2012-02-22
DK1477187T3 (da) 2011-10-31
US20090148499A1 (en) 2009-06-11
RU2175561C2 (ru) 2001-11-10
CA2762921A1 (en) 1996-12-05
CA2222889A1 (en) 1996-12-05
US20060067966A1 (en) 2006-03-30
ES2368951T9 (es) 2012-04-09
US20060204543A1 (en) 2006-09-14
EP2298353A1 (en) 2011-03-23

Similar Documents

Publication Publication Date Title
PT1477187E (pt) Formulação para a libertação controlada de fármacos pela combinação de agentes hidrófilos e hidrófobos
RU98100252A (ru) Усовершенствованный состав для регулируемого выделения лекарственных средств посредством комбинирования гидрофильных и гидрофобных агентов
UA29563C2 (uk) Мікрокапсула для тривалого вивільнення фізіологічно активного пептиду
IL209703A0 (en) Controlled release hydrocodone formulations
DE69329400D1 (de) L-Dopa Ester enthaltende Zusammensetzung
WO2001043749A3 (en) Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
CA2235919A1 (en) Non-polymeric sustained release delivery system
FR2811571B1 (fr) Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
PL323832A1 (en) Composition for prolonged release of human growth hormone
AU2223095A (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
JPH09506331A (ja) 乾癬処置の治療システム
AU5784096A (en) Method and composition for prevention of posterior capsule opacification
CA2187153A1 (en) Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules